Researchers have successfully demonstrated how an electronic device implanted directly into the brain can detect, stop and even prevent epileptic seizures.
These thin, organic films do minimal damage in the brain, and their electrical properties are well-suited for these types of applications.
The researchers, from the University of Cambridge, the École Nationale Supérieure des Mines and INSERM in France, implanted the device into the brains of mice, and when the first signals of a seizure were detected, delivered a native brain chemical which stopped the seizure from progressing. The results, reported in the journal Science Advances, could also be applied to other conditions including brain tumours and Parkinson’s disease.
The work represents another advance in the development of soft, flexible electronics that interface well with human tissue. “These thin, organic films do minimal damage in the brain, and their electrical properties are well-suited for these types of applications,” said Professor George Malliaras, the Prince Philip Professor of Technology in Cambridge’s Department of Engineering, who led the research.
While there are many different types of seizures, in most patients with epilepsy, neurons in the brain start firing and signal to neighbouring neurons to fire as well, in a snowball effect that can affect consciousness or motor control. Epilepsy is most commonly treated with anti-epileptic drugs, but these drugs often have serious side effects and they do not prevent seizures in three out of 10 patients.
In the current work, the researchers used a neurotransmitter which acts as the ‘brake’ at the source of the seizure, essentially signalling to the neurons to stop firing and end the seizure. The drug is delivered to the affected region of the brain by a neural probe incorporating a tiny ion pump and electrodes to monitor neural activity.
When the neural signal of a seizure is detected by the electrodes, the ion pump is activated, creating an electric field that moves the drug across an ion exchange membrane and out of the device, a process known as electrophoresis. The amount of drug can be controlled by tuning the strength of the electric field.
“In addition to being able to control exactly when and how much drug is delivered, what is special about this approach is that the drugs come out of the device without any solvent,” said lead author Dr Christopher Proctor, a postdoctoral researcher in the Department of Engineering. “This prevents damage to the surrounding tissue and allows the drugs to interact with the cells immediately outside the device.”
The researchers found that seizures could be prevented with relatively small doses of drug representing less than 1% of the total amount of drug loaded into the device. This means the device should be able to operate for extended periods without needing to be refilled. They also found evidence that the delivered drug, which was in fact a neurotransmitter that is native to the body, was taken up by natural processes in the brain within minutes which, the researchers say, should help reduce side effects from the treatment.
Although early results are promising, the potential treatment would not be available for humans for several years. The researchers next plan to study the longer-term effects of the device in mice.
Malliaras is establishing a new facility at Cambridge which will be able to prototype these specialised devices, which could be used for a range of conditions. Although the device was tested in an animal model of epilepsy, the same technology could potentially be used for other neurological conditions, including the treatment of brain tumours and Parkinson’s disease.
The Latest on: Epilepsy
via Google News
The Latest on: Epilepsy
- Ovid Therapeutics to Present at the American Epilepsy Society (AES) 2020 Virtual Congresson November 23, 2020 at 1:20 pm
(GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today ...
- Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the 2020 Virtual Annual Meeting of the American Epilepsy Society (AES)on November 23, 2020 at 9:24 am
- COVID-19, Seizures and Epilepsy: What to Knowon November 23, 2020 at 7:45 am
Early reports highlighted seizures in patients with COVID-19, but now it seems that the incidence of seizures is about what we would expect for any group of critically ill patients. Seizures may occur ...
- Global Childhood Absence Epilepsy Treatment Market 2020 Segment Overview, Company Profiles, Regional Analysis and Forecast 2026on November 22, 2020 at 7:01 pm
The latest market research report titled Global Childhood Absence Epilepsy Treatment Market 2020 by Company, Regions, Type and Application, Forecast to 2026 reveals the overview of the global industry ...
- Samrina Hanif: Coping with epilepsy and COVID-19on November 21, 2020 at 8:00 pm
More than 3 million people in the United States live with epilepsy, a chronic brain disorder that causes seizures. This year, COVID-19 has added to the challenges these individuals face.
- Epilepsy Foundation met pandemic challenges head-onon November 18, 2020 at 10:02 am
If there's a will, there's a way, and the Epilepsy Foundation of Northeastern New York has tackled obstacles presented by the COVID-19 pandemic in the same manner it has in trying to find a cure for ...
- Epilepsy Monitoring Devices Market Changing Dynamics Of Competition With Forecast To 2025on November 18, 2020 at 7:00 am
Industry Insights The Global Epilepsy Monitoring Devices market is anticipated to reach XX USD billion with CAGR of xx over the forecast period 2020 2025 The report plans to give a review of The ...
- Cerebral Therapeutics Announces Enrollment of First Patient in a Multicenter Randomized Controlled Phase 2b Trial in Epilepsyon November 17, 2020 at 5:34 am
Cerebral Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative treatments for neurological diseases, today announced that the first patient has been enrolled in a Phase 2b ...
- Q And A: Treatments other than medication can be effective for drug-resistant epilepsyon November 12, 2020 at 1:34 pm
My daughter is in her 30s, and she has had epilepsy for years. Lately, her medication hasn't been effectively preventing seizures. She's on a new medication, but her health care provider says that ...
- WHA73 endorses resolutions on meningitis control and epilepsy, roadmap on neglected tropical diseaseson November 12, 2020 at 12:20 pm
Member States recommended the adoption of two resolutions on meningitis control and epilepsy at the 73rd World Health Assembly on Thursday (November 12). Committee A, which focuses on programme and ...
via Bing News